In the previous 12 months, the patients had an average of 5.6 episodes of herpes labialis. The median age of these patients was 44 years (range 18 to 80 years), 72% were women, and 91% were white.

BioAlliance Pharma announced the launch of Sitavig (acyclovir) in the U.S. by Innocutis Holdings LCC for the treatment of recurring Herpes labialis. Sitavig is a nucleoside analog that comes in ...

McCune et al. [14] enrolled 47 immunocompetent patients with recurrent herpes labialis outbreaks in a study to determine the efficacy of oral lysine for prophylaxis.

The Herpes Labialis Treatment Market is growing steadily as awareness about cold sore management increases. Herpes labialis, commonly known as cold sores, is caused by the herpes simplex virus (HSV-1) ...

While 48% of participants reported feeling upset by images of psoriasis, mostly due to color, scale, thickness and size of lesions (95% CI, 35.1-61.3), a significantly higher number of survey ...

Sitavig® (acyclovir), 50mg Muco-Adhesive Buccal Tablet is indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults. IMPORTANT SAFETY INFORMATION ...

A case of recurrent psychosis of an organic type associated with proved herpes-simplex labialis is presented. This illness began with a typical herpetic stomatitis and encephalitis.

Second BioAlliance Pharma drug registered in the US An effective and innovative medicine for the treatment of a frequent infection, recurrent Herpes labialis in adults Paris, April 15, 2013 ...

Bacillus Calmette-Guérin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trial. eClinicalMedicine, 64, 102203. doi: 10.1016/j.eclinm.2023.102203 ...

ANN ARBOR, Mich., March 17 /PRNewswire/ -- NanoBio Corporation reported top-level findings today from its phase 2b study of NB-001, a topical lotion to treat herpes labialis (cold sores). The ...